LifeMD (NASDAQ:LFMD) Hits New 12-Month High at $12.50

LifeMD, Inc. (NASDAQ:LFMD)’s stock price reached a new 52-week high during trading on Thursday . The company traded as high as $12.50 and last traded at $12.49, with a volume of 602630 shares changing hands. The stock had previously closed at $11.64.

Analyst Ratings Changes

A number of brokerages have issued reports on LFMD. BTIG Research raised their price target on shares of LifeMD from $13.00 to $14.00 and gave the stock a “buy” rating in a report on Tuesday, April 23rd. HC Wainwright raised their price target on LifeMD from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Thursday, January 11th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $10.40.

LifeMD Price Performance

The stock has a market cap of $511.53 million, a PE ratio of -17.87 and a beta of 1.38. The business has a fifty day simple moving average of $9.92 and a two-hundred day simple moving average of $7.95. The company has a current ratio of 1.22, a quick ratio of 1.15 and a debt-to-equity ratio of 3.22.

LifeMD (NASDAQ:LFMD) last posted its quarterly earnings data on Monday, March 11th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.02. The firm had revenue of $44.86 million during the quarter, compared to the consensus estimate of $40.65 million. Research analysts forecast that LifeMD, Inc. will post -0.14 earnings per share for the current year.

Institutional Investors Weigh In On LifeMD

Hedge funds and other institutional investors have recently bought and sold shares of the business. G2 Investment Partners Management LLC boosted its position in shares of LifeMD by 23.9% in the 4th quarter. G2 Investment Partners Management LLC now owns 688,050 shares of the company’s stock worth $5,704,000 after purchasing an additional 132,850 shares in the last quarter. Hsbc Holdings PLC bought a new stake in LifeMD in the fourth quarter worth $815,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in LifeMD in the third quarter worth $577,000. Cantor Fitzgerald L. P. purchased a new stake in shares of LifeMD in the fourth quarter worth $653,000. Finally, Jump Financial LLC bought a new position in shares of LifeMD during the third quarter valued at $465,000. Hedge funds and other institutional investors own 35.52% of the company’s stock.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.